340 related articles for article (PubMed ID: 10022822)
21. Invariant chain controls the activity of extracellular cathepsin L.
Fiebiger E; Maehr R; Villadangos J; Weber E; Erickson A; Bikoff E; Ploegh HL; Lennon-Duménil AM
J Exp Med; 2002 Nov; 196(9):1263-9. PubMed ID: 12417635
[TBL] [Abstract][Full Text] [Related]
22. Distinct properties of prohormone thiol protease (PTP) compared to cathepsins B, L, and H: evidence for PTP as a novel cysteine protease.
Azaryan AV; Hook VY
Arch Biochem Biophys; 1994 Oct; 314(1):171-7. PubMed ID: 7944391
[TBL] [Abstract][Full Text] [Related]
23. The alpha1/2 helical backbone of the prodomains defines the intrinsic inhibitory specificity in the cathepsin L-like cysteine protease subfamily.
Guo YL; Kurz U; Schultz JE; Lim CC; Wiederanders B; Schilling K
FEBS Lett; 2000 Mar; 469(2-3):203-7. PubMed ID: 10713271
[TBL] [Abstract][Full Text] [Related]
24. Structure of human procathepsin L reveals the molecular basis of inhibition by the prosegment.
Coulombe R; Grochulski P; Sivaraman J; Ménard R; Mort JS; Cygler M
EMBO J; 1996 Oct; 15(20):5492-503. PubMed ID: 8896443
[TBL] [Abstract][Full Text] [Related]
25. A role for cathepsin L and cathepsin S in peptide generation for MHC class II presentation.
Hsieh CS; deRoos P; Honey K; Beers C; Rudensky AY
J Immunol; 2002 Mar; 168(6):2618-25. PubMed ID: 11884425
[TBL] [Abstract][Full Text] [Related]
26. Crystal structure of wild-type human procathepsin K.
Sivaraman J; Lalumière M; Ménard R; Cygler M
Protein Sci; 1999 Feb; 8(2):283-90. PubMed ID: 10048321
[TBL] [Abstract][Full Text] [Related]
27. Potential sites for processing of the human invariant chain by cathepsins D and E.
Kageyama T; Yonezawa S; Ichinose M; Miki K; Moriyama A
Biochem Biophys Res Commun; 1996 Jun; 223(3):549-53. PubMed ID: 8687433
[TBL] [Abstract][Full Text] [Related]
28. Specificity determinants of human cathepsin s revealed by crystal structures of complexes.
Pauly TA; Sulea T; Ammirati M; Sivaraman J; Danley DE; Griffor MC; Kamath AV; Wang IK; Laird ER; Seddon AP; Ménard R; Cygler M; Rath VL
Biochemistry; 2003 Mar; 42(11):3203-13. PubMed ID: 12641451
[TBL] [Abstract][Full Text] [Related]
29. Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors: S2P2 specificity of human cathepsin O2 in comparison with cathepsins S and L.
Brömme D; Klaus JL; Okamoto K; Rasnick D; Palmer JT
Biochem J; 1996 Apr; 315 ( Pt 1)(Pt 1):85-9. PubMed ID: 8670136
[TBL] [Abstract][Full Text] [Related]
30. The crystal structure of human cathepsin L complexed with E-64.
Fujishima A; Imai Y; Nomura T; Fujisawa Y; Yamamoto Y; Sugawara T
FEBS Lett; 1997 Apr; 407(1):47-50. PubMed ID: 9141479
[TBL] [Abstract][Full Text] [Related]
31. Crystal structure of human cathepsin V.
Somoza JR; Zhan H; Bowman KK; Yu L; Mortara KD; Palmer JT; Clark JM; McGrath ME
Biochemistry; 2000 Oct; 39(41):12543-51. PubMed ID: 11027133
[TBL] [Abstract][Full Text] [Related]
32. Amino acid substitutions in the N-terminal segment of cystatin C create selective protein inhibitors of lysosomal cysteine proteinases.
Mason RW; Sol-Church K; Abrahamson M
Biochem J; 1998 Mar; 330 ( Pt 2)(Pt 2):833-8. PubMed ID: 9480898
[TBL] [Abstract][Full Text] [Related]
33. Delivery of nascent MHC class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells.
Morton PA; Zacheis ML; Giacoletto KS; Manning JA; Schwartz BD
J Immunol; 1995 Jan; 154(1):137-50. PubMed ID: 7995933
[TBL] [Abstract][Full Text] [Related]
34. Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis.
Tolosa E; Li W; Yasuda Y; Wienhold W; Denzin LK; Lautwein A; Driessen C; Schnorrer P; Weber E; Stevanovic S; Kurek R; Melms A; Bromme D
J Clin Invest; 2003 Aug; 112(4):517-26. PubMed ID: 12925692
[TBL] [Abstract][Full Text] [Related]
35. Immunocompetent astrocytes and microglia display major differences in the processing of the invariant chain and in the expression of active cathepsin L and cathepsin S.
Gresser O; Weber E; Hellwig A; Riese S; Régnier-Vigouroux A
Eur J Immunol; 2001 Jun; 31(6):1813-24. PubMed ID: 11433378
[TBL] [Abstract][Full Text] [Related]
36. Crystal structure of human procathepsin X: a cysteine protease with the proregion covalently linked to the active site cysteine.
Sivaraman J; Nägler DK; Zhang R; Ménard R; Cygler M
J Mol Biol; 2000 Jan; 295(4):939-51. PubMed ID: 10656802
[TBL] [Abstract][Full Text] [Related]
37. Proteases involved in MHC class II antigen presentation.
Villadangos JA; Bryant RA; Deussing J; Driessen C; Lennon-Duménil AM; Riese RJ; Roth W; Saftig P; Shi GP; Chapman HA; Peters C; Ploegh HL
Immunol Rev; 1999 Dec; 172():109-20. PubMed ID: 10631941
[TBL] [Abstract][Full Text] [Related]
38. Degradation of mouse invariant chain: roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism.
Villadangos JA; Riese RJ; Peters C; Chapman HA; Ploegh HL
J Exp Med; 1997 Aug; 186(4):549-60. PubMed ID: 9254653
[TBL] [Abstract][Full Text] [Related]
39. Human cathepsin V functional expression, tissue distribution, electrostatic surface potential, enzymatic characterization, and chromosomal localization.
Brömme D; Li Z; Barnes M; Mehler E
Biochemistry; 1999 Feb; 38(8):2377-85. PubMed ID: 10029531
[TBL] [Abstract][Full Text] [Related]
40. Cathepsin L regulates CD4+ T cell selection independently of its effect on invariant chain: a role in the generation of positively selecting peptide ligands.
Honey K; Nakagawa T; Peters C; Rudensky A
J Exp Med; 2002 May; 195(10):1349-58. PubMed ID: 12021314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
